Financial Data and Key Metrics Changes - The company achieved record first quarter sales of $234 million, representing a 22% year-over-year growth [17] - Adjusted EBITDA improved by five percentage points year-over-year, indicating a strong operational performance [22] - Gross margin for Q1 was 51%, consistent with Q4, driven by reduced per unit costs of pumps [22][28] Business Line Data and Key Metrics Changes - In the U.S., sales reached $151 million, a 15% increase year-over-year, driven by healthy pump shipments and strong supply sales [18] - Internationally, sales were $84 million, reflecting a 35% year-over-year growth, supported by demand for the t:slim X2 platform [21] - The product mix between the t:slim X2 and the new Tandem Movi is healthy, with a significant portion of new starts coming from patients converting from multiple daily injections [7][8] Market Data and Key Metrics Changes - Approximately 30% of U.S. lives are now covered under the pharmacy benefit, up from 20% previously, indicating improved market access [19][67] - The company anticipates that sales outside the U.S. will be relatively flat for the remainder of the year due to a timing shift in orders [27] Company Strategy and Development Direction - The company plans to enhance its sales efforts and technology offerings outside the U.S. as it prepares for direct sales in select countries starting in 2026 [15] - New product launches, including the Control IQ Plus algorithm and sensor integrations, are expected to drive growth in both U.S. and international markets [30][32] - The company is focused on improving profitability through increased pricing, margin improvement initiatives, and disciplined cost management [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 2025 commitments despite a dynamic economic environment [23][73] - The company is optimistic about the growth potential from the type two diabetes indication, which more than doubles the addressable market [13][79] - Management reaffirmed guidance for sales, gross margin, and EBITDA for 2025, indicating a strong outlook for the year [24][73] Other Important Information - The company has completed its sales force expansion and territory realignment, which is expected to enhance productivity over the coming quarters [9][39] - The recent FDA clearance of Control IQ Plus for type two diabetes is a significant milestone, with initial commercial efforts already underway [11][13] Q&A Session Summary Question: Update on sales force changes and realignment - Management confirmed that the territory realignment is complete and expects gradual improvement in productivity over the next several quarters [39] Question: Impact of pricing on U.S. sales - Management indicated that pricing contributed approximately 2% to 3% for pumps and around 10% for supplies, suggesting this is a sustainable level moving forward [44][45] Question: Competitive dynamics in international markets - Management noted that the competitive environment remains stable, with strong demand for their technology and products in international markets [88] Question: Expectations for pharmacy channel contributions - Management stated that pharmacy contributions are expected to be modest in 2025, but early experiences indicate significant long-term potential [52][68] Question: Clarification on SIGI development timeline - Management clarified that the termination of the previous agreement allows for more control over the development path, potentially improving time to market [58][59] Question: Gross margin performance and future expectations - Management highlighted that improvements in pump costs and the introduction of Mobi are key factors in achieving long-term gross margin targets [62][63] Question: Type two indication and market access - Management acknowledged that while there is coverage for type two patients, Medicare approval processes may present initial challenges [78][80]

Financial Performance - Total sales for the three months ended March 31, 2025, were $234,422,000, representing a 22.3% increase from $191,674,000 in the same period of 2024[10]. - Gross profit for Q1 2025 was $118,407,000, up from $94,672,000 in Q1 2024, indicating a gross margin improvement[10]. - Net loss for Q1 2025 was $130,556,000, compared to a net loss of $42,715,000 in Q1 2024, indicating a significant increase in losses year-over-year[10]. - For the three months ended March 31, 2025, the company reported a net loss of $130.6 million, compared to a net loss of $42.7 million for the same period in 2024, representing an increase in losses of approximately 206%[15]. - The total interest expense for the three months ended March 31, 2025, was $1.8 million, an increase from $1.6 million in the same period of 2024[81]. Operating Expenses - Operating loss increased to $120,878,000 in Q1 2025 compared to a loss of $41,678,000 in Q1 2024, reflecting higher operating expenses[10]. - Total operating expenses for Q1 2025 were $239.3 million, significantly higher than $136.4 million in Q1 2024, driven by $75.2 million in acquired in-process research and development expenses[10]. - The company reported stock-based compensation expense of $25.489 million for the three months ended March 31, 2025, up from $22.039 million in the same period of 2024, an increase of 11.1%[15]. Assets and Liabilities - Total current assets decreased to $663,435,000 as of March 31, 2025, down from $724,491,000 at the end of 2024[8]. - Total liabilities increased to $766,851,000 as of March 31, 2025, compared to $704,560,000 at the end of 2024[8]. - Stockholders' equity decreased to $155,292,000 as of March 31, 2025, down from $263,098,000 at the end of 2024, reflecting the impact of net losses[8]. - Total assets as of March 31, 2025, were $352.5 million, a decrease from $425.3 million as of December 31, 2024, representing a decline of approximately 17.1%[1]. Cash Flow - Net cash used in operating activities was $18.3 million for the three months ended March 31, 2025, compared to $8.0 million for the same period in 2024, indicating a 129% increase in cash outflow[15]. - Cash and cash equivalents at the end of the period were $53.6 million, down from $59.0 million at the end of the same period in 2024, reflecting a decrease of approximately 7.4%[15]. - The company reported a net cash provided by investing activities of $9.2 million for the first quarter of 2025, contrasting with a net cash used of $5.1 million in the same period of 2024[15]. Research and Development - Research and development expenses rose to $50,215,000 in Q1 2025 from $46,244,000 in Q1 2024, highlighting ongoing investment in innovation[10]. - The company incurred $75.2 million in acquired in-process research and development expenses during the first quarter of 2025, with no such expenses reported in the same period of 2024[15]. Revenue Sources - The company’s revenue is primarily generated from sales of insulin pumps and related products, with revenue recognition occurring upon transfer of control to customers[30]. - Revenue from the United States was $150.6 million, up from $129.8 million in the prior year, while revenue from outside the United States increased to $83.8 million from $61.9 million[100]. - Sales of insulin pumps reached $102.1 million, compared to $87.3 million in the previous year, while supplies and other sales totaled $132.3 million, up from $105.5 million[101]. Investments and Securities - The company held equity method investments valued at $71.0 million as of March 31, 2025, down from $74.5 million at the end of 2024[28]. - The company recognized a loss of $3.5 million from equity method investments for the three months ended March 31, 2025, with no such losses reported in the same period of 2024[29]. - The company’s short-term investments totaled $315.051 million as of March 31, 2025, compared to $369.095 million at December 31, 2024[44]. Warranty and Allowances - As of March 31, 2025, the total product warranty reserve increased to $52.210 million from $51.408 million at December 31, 2024[38]. - The allowance for credit losses decreased to $7.125 million as of March 31, 2025, from $7.251 million at December 31, 2024[49]. - Estimated warranty costs are recorded at shipment, with a four-year warranty on insulin pumps and a six-month warranty on cartridges and infusion sets[36]. Debt and Financing - The company issued $316.3 million in convertible senior notes due 2029 in March 2024, with net proceeds of $306.8 million after costs[67]. - The fair value of outstanding convertible senior notes decreased from $446.9 million on December 31, 2024, to $341.0 million on March 31, 2025, a reduction of about 23.7%[58]. - The initial conversion price for the 2029 notes is approximately $34.56 per share, with a conversion rate of 28.9361 shares per $1,000 principal amount[71]. Legal Matters - The Company is involved in ongoing legal disputes regarding patent infringement claims related to its t:slim X2 insulin pump, with hearings scheduled for June 2025[106][107].

Financial Performance - For the quarter ended December 2024, Tandem Diabetes Care, Inc. reported revenue of $252.45 million, reflecting a 28.3% increase year-over-year [1] - The earnings per share (EPS) was reported at -$0.44, compared to -$0.27 in the same quarter last year, indicating a decline [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $255.18 million, resulting in a revenue surprise of -1.07% [1] - The company experienced an EPS surprise of -76.00%, with the consensus EPS estimate being -$0.25 [1] Key Metrics - Shares of Tandem Diabetes Care have returned -8.4% over the past month, while the Zacks S&P 500 composite changed by -2.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3] Geographic Sales - United States sales reached $214.56 million, exceeding the average estimate of $190.90 million by three analysts, representing a year-over-year increase of 42.2% [4] - Sales outside the United States were reported at $68.09 million, significantly surpassing the average estimate of $59.87 million, with a year-over-year change of 148291.5% [4] - Pump sales in the United States totaled $98.44 million, slightly below the average estimate of $101.47 million, marking a 19.5% year-over-year increase [4] - Supplies and other sales in the United States were $85.92 million, compared to the average estimate of $89.43 million, reflecting a 6% year-over-year change [4] - Pump sales outside the United States were $25.77 million, exceeding the average estimate of $19.85 million, with a year-over-year increase of 47.2% [4] - Supplies and other sales outside the United States reached $42.32 million, surpassing the average estimate of $40.50 million, indicating a 14.9% year-over-year change [4] - Total revenue from supplies and other was $128.24 million, slightly below the average estimate of $128.87 million [4] - Revenue from pumps was reported at $124.21 million, exceeding the average estimate of $121.53 million [4]

Core Insights - Tandem Diabetes Care, Inc. (TNDM) is expected to report a quarterly loss of $0.25 per share, reflecting a 7.4% increase compared to the same period last year. Revenue is forecasted at $255.18 million, indicating a year-over-year increase of 29.7% [1] Financial Projections - Analysts estimate 'Sales- Pump- United States' to be $101.47 million, representing a 23.2% increase from the previous year [4] - 'Sales- Supplies and Other- United States' is projected at $89.43 million, showing a 10.3% increase year over year [4] - 'Geographic Sales- Outside the United States' is expected to reach $59.87 million, indicating a 30.5% year-over-year change [5] - 'Geographic Sales- United States' is forecasted at $190.90 million, reflecting a 26.5% increase from the prior year [5] - 'Sales- Supplies and Other- Outside the United States' is estimated at $40.50 million, suggesting a 10% year-over-year increase [6] - 'Sales- Pump- Outside the United States' is projected to be $19.85 million, indicating a 13.3% increase year over year [6] Market Performance - Shares of Tandem Diabetes Care have declined by 10.7% over the past month, while the Zacks S&P 500 composite has decreased by 1.8% [7] - TNDM holds a Zacks Rank of 3 (Hold), suggesting it is expected to perform in line with the overall market in the near future [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q _____________________________________________________________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the T ...